Loxapine

Generic Name: Loxapine

Brand Names: Adasuve, Xylac

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₈ClN_₃O

CAS Number: 1977-10-2

Unique Ingredient Identifier: LER583670J

Background: An antipsychotic agent used in schizophrenia. [PubChem]

Indication: For the management of the manifestations of psychotic disorders such as schizophrenia

Associated Conditions: Acute Agitation, Schizophrenia

Clinical Trials

Loxapine in the Management of Restlessness During Mechanical Ventilation Weaning

Phase 4

Completed

Conditions: Restlessness

Interventions: Drug: loxapine
Drug: Placebo

First Posted Date: 2010-09-02

Last Posted Date: 2014-07-18

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 100

Registration Number: NCT01193816

Locations: 🇫🇷
Hôpital Louis Mourier, Colombes, France

Staccato Loxapine Pulmonary Safety in Patients With COPD

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Inhaled Placebo
Drug: Inhaled Loxapine

First Posted Date: 2009-04-29

Last Posted Date: 2017-03-14

Lead Sponsor: Alexza Pharmaceuticals, Inc.

Target Recruit Count: 53

Registration Number: NCT00889837

Locations: 🇺🇸
Spartanburg Medical Research, Spartanburg, South Carolina, United States

Staccato Loxapine PK in Smokers and Nonsmokers

Phase 1

Completed

Conditions: Smoking, Cigarette

Interventions: Drug: Inhaled Loxapine 10 mg

First Posted Date: 2009-04-02

Last Posted Date: 2017-03-15

Lead Sponsor: Alexza Pharmaceuticals, Inc.

Target Recruit Count: 35

Registration Number: NCT00873769

Locations: 🇺🇸
Covance Clinical Research Unit, Inc., Evansville, Indiana, United States

Staccato Loxapine Thorough QT/QTc Study

Phase 1

Completed

Conditions: Thorough QT/QTc Study

Interventions: Drug: Inhaled loxapine
Drug: Inhaled placebo
Drug: Oral moxifloxacin
Drug: Oral placebo

First Posted Date: 2009-04-02

Last Posted Date: 2019-10-30

Lead Sponsor: Alexza Pharmaceuticals, Inc.

Target Recruit Count: 48

Registration Number: NCT00874237

Locations: 🇺🇸
Covance Clinical Research Unit Inc., Evansville, Indiana, United States

Staccato Loxapine Pulmonary Safety in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Inhaled Placebo
Drug: Inhaled Loxapine

First Posted Date: 2008-11-11

Last Posted Date: 2019-03-11

Lead Sponsor: Alexza Pharmaceuticals, Inc.

Target Recruit Count: 30

Registration Number: NCT00789360

Locations: 🇺🇸
Northeast Medical Research, North Dartmouth, Massachusetts, United States

Staccato Loxapine in Agitated Patients With Bipolar Disorder

Phase 3

Completed

Conditions: Bipolar I Disorder

Interventions: Drug: Inhaled Placebo
Drug: Inhaled loxapine 5 mg
Drug: Inhaled loxapine 10 mg

First Posted Date: 2008-07-25

Last Posted Date: 2017-07-26

Lead Sponsor: Alexza Pharmaceuticals, Inc.

Target Recruit Count: 314

Registration Number: NCT00721955

Locations: 🇺🇸
Collaborative NeuroScience Network, Inc., Garden Grove, California, United States
🇺🇸
Synergy Escondido, Escondido, California, United States
🇺🇸
FutureSearch Trials, Austin, Texas, United States

and more 3 locations

Fasting Study of Loxapine Succinate Capsules 25 mg and Loxitane® Capsules 25 mg

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Loxitane® Capsules 25 mg
Drug: Loxapine Succinate Capsules 25 mg

First Posted Date: 2008-04-01

Last Posted Date: 2024-04-24

Lead Sponsor: Mylan Pharmaceuticals Inc

Target Recruit Count: 53

Registration Number: NCT00648778

Locations: 🇺🇸
Kendle International Inc., Morgantown, West Virginia, United States

Staccato Loxapine in Agitated Patients With Schizophrenia

Phase 3

Completed

Conditions: Patients With Schizophrenia and Acute Agitation

Interventions: Drug: Inhaled loxapine 5 mg
Drug: Inhaled loxapine 10 mg
Drug: Inhaled placebo

First Posted Date: 2008-03-05

Last Posted Date: 2017-07-26

Lead Sponsor: Alexza Pharmaceuticals, Inc.

Target Recruit Count: 344

Registration Number: NCT00628589

Locations: 🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States

Staccato Loxapine Single Dose PK

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: inhaled Loxapine 5 mg
Drug: inhaled Loxapine 0.625 mg
Drug: inhaled Loxapine 1.25 mg
Drug: inhaled Loxapine 2.5 mg
Drug: inhaled Loxapine 10 mg
Drug: inhaled Placebo (0 mg)

First Posted Date: 2007-03-07

Last Posted Date: 2018-11-20

Lead Sponsor: Alexza Pharmaceuticals, Inc.

Target Recruit Count: 50

Registration Number: NCT00444028

Locations: 🇺🇸
Covance Clinical Research Unit Inc., d/b/a Covance GFI Research, Evansville, Indiana, United States

Staccato Loxapine in Agitation (Proof of Concept)

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: Inhaled Loxapine 5 mg
Drug: Inhaled Placebo
Drug: Inhaled Loxapine 10 mg

First Posted Date: 2006-08-29

Last Posted Date: 2018-01-02

Lead Sponsor: Alexza Pharmaceuticals, Inc.

Target Recruit Count: 129

Registration Number: NCT00369577

Locations: 🇺🇸
Pacific Clinical Research Medical Group, 1317 West Foothill Blvd, Suite 200,, Upland, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy